Loading...
Pharmaron Beijing Co., Ltd.
3759.HK•HKSE
Healthcare
Biotechnology
HK$15.94
HK$0.36(2.31%)
Pharmaron Beijing Co., Ltd. (3759.HK) Financial Performance & Statements
Review Pharmaron Beijing Co., Ltd.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
6.39%
↑ 6.39%
Operating Income Growth
13.88%
↑ 13.88%
Net Income Growth
12.008%
↑ 12.008%
Operating Cash Flow Growth
-6.42%
↓ 6.42%
Operating Margin
17.32%
↑ 17.32%
Gross Margin
34.43%
↑ 34.43%
Net Profit Margin
14.71%
↑ 14.71%
ROE
13.82%
↑ 13.82%
ROIC
10.94%
↑ 10.94%
Pharmaron Beijing Co., Ltd. (3759.HK) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Pharmaron Beijing Co., Ltd. stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $3.46B | $3.21B | $2.90B | $2.64B |
| Cost of Revenue | $2.24B | $2.10B | $2.00B | $1.80B |
| Gross Profit | $1.22B | $1.12B | $904.80M | $842.50M |
| Gross Profit Ratio | $0.35 | $0.35 | $0.31 | $0.32 |
| R&D Expenses | $137.007M | $124.45M | $105.35M | $93.61M |
| SG&A Expenses | -$672.51M | $468.67M | $433.01M | $460.29M |
| Operating Expenses | $739.50M | $717.24M | $538.11M | $554.15M |
| Total Costs & Expenses | $2.98B | $2.81B | $2.54B | $2.35B |
| Interest Income | $8.25M | $14.50M | $75.21M | $7.13M |
| Interest Expense | $50.30M | $55.17M | $67.69M | $70.57M |
| Depreciation & Amortization | $42.46M | $52.20M | $277.41M | $182.60M |
| EBITDA | $519.68M | $450.19M | $1.04B | $471.20M |
| EBITDA Ratio | $0.15 | $0.14 | $0.36 | $0.18 |
| Operating Income | $477.23M | $397.99M | $366.69M | $288.35M |
| Operating Income Ratio | $0.14 | $0.12 | $0.13 | $0.11 |
| Other Income/Expenses (Net) | -$7.84M | -$2.97M | -$2.60M | $12.69M |
| Income Before Tax | $469.39M | $395.02M | $976.05M | $281.10M |
| Income Before Tax Ratio | $0.14 | $0.12 | $0.34 | $0.11 |
| Income Tax Expense | $124.44M | $108.76M | $91.21M | $52.70M |
| Net Income | $371.55M | $308.40M | $882.85M | $230.56M |
| Net Income Ratio | $0.11 | $0.10 | $0.30 | $0.09 |
| EPS | $0.17 | $0.17 | $0.50 | $0.13 |
| Diluted EPS | $0.17 | $0.17 | $0.50 | $0.13 |
| Weighted Avg Shares Outstanding | $1.79B | $1.79B | $1.77B | $1.79B |
| Weighted Avg Shares Outstanding (Diluted) | $1.79B | $1.79B | $1.78B | $1.79B |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan